Clinical stage II non-small cell lung cancer: can we "just give adjuvant therapy"?

ABSTRACT:

Background

Advances in multimodal therapy have reshaped treatment paradigms for clinical stage II (cII) non-small cell lung cancer (NSCLC), yet optimal treatment sequencing remains controversial. We sought to investigate predictors of adjuvant uptake, accuracy of clinical staging, and oncologic outcomes in patients undergoing upfront surgical resection.

Methods

The retrospective analysis was completed of the National Cancer Database (NCDB) for patients with cII disease from 2015 to 2019 who underwent surgical resection. Patients were stratified by receipt of adjuvant therapy (AT). Rates of uptake, pathologic staging, and survival outcomes were analyzed. Cox regression and Kaplan-Meier curves were used to evaluate overall survival (OS) in propensity-score matched cohorts.

SUBMITTER: Jindani R 

PROVIDER: S-EPMC12780408 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature